|
|
 |
Online Review #6
Because bone metastases occur in 75% of women with advanced breast cancer, investigators are seeking ways to improve bone quality in these women and therefore reduce such complications as bone fracture and spinal cord compression. This online review summarizes the findings of a Phase II trial comparing an investigative monoclonal antibody, denosumab, with intravenous bisphosphonates, the standard of care for this condition. Lisa A. Carey, MD, provides expert commentary on the trial results. This online review represents Course 8 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Audio Interview #6
Julie R. Brahmer, MD, describes how gender differences affect biological risk and survival rates in non�small-cell lung cancer (NSCLC), as well as factors that affect tumor biology, such as k-RAS and EGFR mutations. Dr. Brahmer also discusses the differences between smokers and never-smokers, and whether or not to recommend that patients with lung cancer stop smoking. This audio interview is part of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Tx Reporter #1
In this case-based Tx Reporter newsletter, Lisa A. Carey, MD, ScM, examines recent advances in adjuvant therapy and considers options for a young breast-feeding patient with a high-risk stage II breast cancer. Through this case, Dr. Carey illustrates how prognostic criteria can be used to select an individualized treatment appropriate for each patient. This is Course 7 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Online Review #5
Tumors treated with anti-VEGF (vascular endothelial growth factor) agents commonly become resistant to treatment. This online review identifies a myeloid cell subtype that may play a role in the development of resistance by tumors to anti-VEGF therapy. Mark Pegram, MD, provides expert commentary on these findings. This online review represents Course 6 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Audio Interview #1
William J. Gradishar, MD, describes the latest clinical research illustrating the role of predictive markers in breast cancer therapy to achieve maximal response and progression-free survival. Dr. Gradishar also provides his expert recommendations on how to select among endocrine therapies, chemotherapies, and targeted treatments based on the results of endocrine receptor testing and HER2 testing. This audio interview represents Course 5 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Online Review #8
While chemotherapy has improved short-term survival in patients with small-cell lung cancer (SCLC), long-term survival has not been as promising, attributable to the incidence of brain metastases that approaches 80% at 2 years. This article review reports on the findings of a randomized trial comparing survival and other outcomes for prophylactic cranial irradiation in patients with extensive SCLC. Expert commentary from Hak Choy, MD, is also provided. This online review represents Course 15 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Tx Reporter
In this online case-based newsletter, Julie R. Brahmer, MD considers the case of a patient with metastatic non–small-cell lung cancer (NSCLC), demonstrating decisions to gain survival time with first- and second-line therapies while preserving the patient's comfort and performance status. This newsletter represents Course 13 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #4
This online review presents data showing that women over 65 years old who have node-positive breast cancer may be more vulnerable to toxicity complications with certain chemotherapy regimens. Features expert insights by William J. Gradishar, MD, FACP. This online review represents Course 4 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Online Review #3
This online review presents data showing that aromatase inhibitors may have a role as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer with axillary lymph node metastasis. Expert commentary on these findings is provided by Marc L. Citron, MD. This online review represents Course 3 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Online Review #7
Both preclinical and clinical trials have suggested that oral inhibitors of the epidermal growth factor receptor (EGFR) axis might be useful in treating patients with bronchioloalveolar carcinoma (BAC). The Southwest Oncology Group's report on the results of the largest prospective trial to date of the EGFR tyrosine kinase inhibitor gefitinib in this population is presented here, along with expert commentary on these findings by Alan B. Sandler, MD. This online review represents Course 14 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #6
Roy S. Herbst, MD, PhD, examines the results of a retrospective study of patients diagnosed with NSCLC that compared patients undergoing concurrent chemoradiation with those who received induction chemotherapy prior to chemoradiation. This study was conducted to determine what role induction therapy might have in extending overall survival in this patient group. This online review represents Course 12 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #2
This posting addresses the potential for breast cancer patients with unique needs to benefit from luteinizing hormone-releasing hormone (LHRH) agonists, a drug class that is new to the breast cancer setting. Expert commentary on these topics is provided by Lisa A. Carey, MD, ScM. This online review represents Course 2 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Online Tx Reporter
Harvey I. Pass, MD, and Alan B. Sandler, MD, discuss a patient with early-stage NSCLC, demonstrating the importance of staging and evaluating initial patient and tumor characteristics and then using these findings to make treatment decisions. Audio commentary from Roy S. Herbst, MD, PhD, is also provided. This newsletter represents Course 9 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Audio Interview #4
Listen as Alan B. Sandler, MD, describes clinical research that supports the use of epidermal growth factor receptor (EGFR) and other targeted therapies for treatment of advanced non–small-cell lung cancer (NSCLC). Dr. Sandler examines current practices and investigational uses of erlotinib, gefitinib, cetuximab, and novel therapies in development. This audio interview represents Course 11 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #5
Amplification of the proto-oncogene MET may be implicated in the development of resistance to gefitinib in patients with NSCLC. Roy S. Herbst, MD, PhD, reviews new study data on this recently discovered genetic mutation and the associated treatment implications for NSCLC patients who develop acquired resistance to gefitinib and other tyrosine kinase inhibitors. This online review represents Course 10 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #1
Learn about the impact of BRCA1 and BRCA2 mutations on tumor size and the potential role these mutations play in the prognosis of hereditary breast cancer. The use or nonuse of chemotherapy to predict survival and outcomes in both carriers and noncarriers of mutated BRCA genes is also discussed. This online review represents Course 1 of The Advanced Certificate Program: Breast Cancer Management. |
 |
Certificate Program—New!
Register now for this free and convenient yearlong CME/CE/CPE program offering clinicians current cutting-edge information targeting the management of breast cancer. Presented by our faculty of outstanding oncologists led by co-chairs Harold J. Burstein, MD, PhD, and Mark Pegram, MD, this comprehensive 19-course curriculum promises to challenge you with practical discussions about diagnostic techniques, methodologies, and treatment options to help facilitate your care of patients with breast cancer. |
 |
Audio Interview #3
Learn about new and emerging chemotherapeutic and antiangiogenic agents, and their potential future role in the care of patients with non–small-cell lung cancer (NSCLC). In this audio interview, Roy S. Herbst, MD, PhD, describes clinical research that supports the latest improvements in cytotoxic and biological treatments for NSCLC. This audio interview represents Course 8 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #4
Harvey I. Pass, MD, examines the PET Predictive Ratio (PPR) and discusses how the PPR can assist in predicting lymph node pathology in patients with non–small-cell lung cancer (NSCLC) with mediastinal involvement. This online review represents Course 7 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #3
Alan B. Sandler, MD, describes a new concept by which angiogenesis affects cancer outcomes, the normalization hypothesis, and the findings of a trial of angiogenesis inhibition in non–small-cell lung cancer. This online review represents Course 6 of The Advanced Certificate Program: Lung Cancer Management. |
On-Demand Webcast |
Click Here to View the On-Demand Webcast!
Examine the prevalence of chemotherapy-induced nausea and vomiting (CINV) and pain in breast cancer patients, the impact of these events on refusal/delay of treatment, and specific problems in managing acute, delayed and breakthrough CINV. Discussion includes management with current and novel products, including neuromodulation/cannibinoids.
|
 |
Online Tx Reporter
In NSCLC Basics—Screening and Detection, Harvey I. Pass, MD, examines the controversial issue of lung cancer screening, illustrated by a relevant patient case. This online newsletter also features brief clickable audio comments by co-chair Corey J. Langer, MD, FACP, that provide additional insights on this topic. This newsletter represents Course 5 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Audio Interview #2
As a clinician, you rely on proper and complete clinical staging of
non–small-cell lung cancer (NSCLC) for prognostic information and to select optimal stage-specific treatment options. Learn more about determining NSCLC disease stage and developing an individualized multimodality treatment plan that takes into account current data and controversies. This audio interview represents Course 4 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #2
In The Seesaw Odyssey of Irinotecan in the Therapy of Small-Cell Lung Carcinoma, Corey J. Langer, MD, FACP, discusses the potential role of topoisomerase-1 inhibition in the management of small cell lung cancer by exploring both the history and current research involving irinotecan and topotecan in this setting. This online review represents Course 3 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Audio Interview #1
Optimal treatment of lung cancer requires clinicians to remain informed regarding standard treatment guidelines as they evolve. Learn about the latest data and guideline-based approaches to treating both small-cell and non-small-cell lung cancer in this interview with Corey J. Langer, MD, FACP. Listen online or download MP3 audio file. This audio interview represents Course 2 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Review #1
In What's New in State-of-the-Art Adjuvant Therapy in Resectable (I-IIIA) Lung Cancer?, Julie R. Brahmer, MD, discusses the potential role of new gene analysis models for assessing the risk of recurrence and the potential role of the expression of newly identified genes as predictors of benefit from adjuvant chemotherapy. This online review represents Course 1 of The Advanced Certificate Program: Lung Cancer Management. |
 |
Online Posting #1
In What's New in State-of-the-Art Adjuvant Therapy in Resectable (I-IIIA) Lung Cancer?, Julie R. Brahmer, MD, discusses the potential role of new gene analysis models for assessing the risk of recurrence and the potential role of the expression of newly identified genes as predictors of benefit from adjuvant chemotherapy. This online posting represents Course 1 of The Advanced Certificate Program: Lung Cancer Management. |
Certificate Program |
Certificate Program!
Enroll today in this free yearlong CME/CE program, which provides clinicians with up-to-date information about the management of lung cancer. This outstanding program features an expert faculty co-chaired by Roy S. Herbst, MD, PhD, and Corey J. Langer, MD, FACP, and a comprehensive curriculum of 24 web-based courses. Get timely and practical information that you can immediately use in caring for your patients with lung cancer. |
On-Demand Webcast |
Click Here to View the On-Demand Webcast!
What Pharmacists Need to Know About Targeted Therapies provides oncology pharmacists involved in the care of cancer patients the latest data on the use of targeted therapies in the treatment of solid tumors. |
Tx Reporter & Audio Series |
Click Here to Download or Order this Tx Reporter & Audio Series!
While the use of bisphosphonates in the management of bone metastases and cancer-treatment-induced bone loss is the current standard of care, there are still many areas of ambiguity that impact clinicians as they decide how to treat patients with these devastating complications of cancer. In this five-part, case-based Tx Reporter and audio CD series, our expert faculty will address the treatment of skeletal-related complications in patients with a variety of tumor types. |
On-Demand Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View the On-Demand Webcast!
This program, featuring highlights of presentations from the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO), describes exciting new developments in the use of targeted therapy in metastatic and early stage disease, including expanded use of current agents and promising new drugs. |
On-Demand Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View the On-Demand Webcast!
This timely interactive program, featuring highlights of presentations from the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO), critically examines how results from recent clinical trials with novel targeted therapies may impact the treatment of patients with non-small–cell lung cancer (NSCLC). |
Daily Podcast |
This activity has reached its termination date and no longer offers continuing education credit.
Daily Podcast
News and Views on NSCLC from the 2006 ASCO Annual Meeting is a series of lively 15-minute interviews conducted with top oncology experts who provide their insights on the latest scientific advances in treating lung cancer and discuss highlights of some of the presentations and poster sessions from the meeting. |
CE Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View Webcast
Myelodysplastic syndromes (MDS) and multiple myeloma (MM) remain among the more challenging cancers to manage. Although numerous single and combination treatment regimens have been explored in these diseases, morbidity and mortality remain high and new approaches are needed.
Recently, several new classes of agents—including proteasome inhibitors, methylation inhibitors, and immunomodulators—have shown promising results in treating patients with MDS and MM. It is essential for pharmacists involved in the care of patients with these disorders to keep apprised of both current and prospective therapeutic options. In this CE webcast, Pharmacist's Update on Myelodysplastic Syndromes and Multiple Myeloma, our panel of experts will discuss some of these exciting emerging drugs, focusing on their mechanisms of action, the management of related side effects and drug-drug interactions, and new strategies to incorporate these agents into existing treatment paradigms. |
 Weblog and Forum |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to participate!
Practice Manager Insider is written for practice managers who are interested in furthering the efficiency of their oncology practices. Practice Manager Insider offers continuing education credit, research, resources, and ongoing dialogue that provides a forum for oncology practice managers to read and comment on the latest Medicare changes, as well as strategies to improve practice efficiencies in oncology.
|
CE Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View Webcast
We hope that you will be able to join us on the Internet for Angiogenesis Inhibitors in Oncology: Implications for Health System Pharmacies, a CE on-demand webcast. Designed specifically for pharmacists by experts in the field, the webcast focuses on the mechanisms of action of these drugs, their safety and efficacy, and how best to incorporate them into treatment protocols. In light of the 2005 changes in Medicare reimbursement, the webcast also discusses the requirements for reimbursement and the effects these new regulations have on planning treatment for oncology patients. |
CME/CE Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View Webcast
Join us on the Internet for this on-demand webcast to view the activity at your convenience. In ASCO 2005: Paradigm Shift in Breast Cancer Treatment, authorities in breast cancer will address some of your most important concerns regarding progress in endocrine therapy and chemotherapies, and pioneering developments in biologic therapy. The presentation also includes an insightful overview on management and monitoring of patients on emerging therapies. It is sure to be an informative and valuable webcast. |
CME/CE Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View Webcast
Join us on the Internet for this on-demand webcast to view the activity at your convenience. 2005 Cancer Update: What's New in Angiogenesis? (Highlights from the American Society of Clinical Oncology Annual Meeting) will address some of your most important concerns regarding emerging therapies that target angiogenesis. It is sure to be an informative and valuable webcast. |
Interactive CD-ROM |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to Order Your CD-ROM
The Medicare Reform changes that have taken effect in 2005 will impact every oncology practice in the United States with unparalleled shifts in the way oncology services are reimbursed. That's why you cannot afford to miss Medicare 2005: Improving Oncology Practice Performance. This comprehensive CE CD-ROM is directed at providing office-based oncology practices with the necessary knowledge to operate a maximum-efficiency office. Reserve your copy now to learn how to make your practice operate more efficiently and how best to thrive within the new and evolving reimbursement environment. |
Interactive CD-ROM |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to Order Your CD-ROM!
Recent advances in lung cancer treatment are improving survival and overall quality of life in patients with non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Lung Cancer Case Files: Current Strategies to Optimize Therapy, a free CME CD-ROM, focuses on the very latest advances in lung cancer management, including strategies for improved diagnosis, staging, and treatment. In this case-based educational activity, we discuss important data on lung cancer treatment, including the newest research, and formulate specific patient-care strategies illustrated in sample clinical cases. Each case highlights therapeutic decisions that aim to improve tumor response, survival, and overall quality of life, including decisions regarding first- and second-line therapy, the optimal duration of therapy, and options for palliative care. |
CME Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Click Here to View Webcast
In a discussion designed for oncologists and urologists, our panel of thought leaders will present the latest data on treatment options for advanced prostate cancer and the role of bisphosphonates in reducing skeletal complications. As a result of this discussion, you will be able to identify prostate cancer patients who are at risk for developing skeletal complications and understand the mechanisms of action by which bisphosphonates minimize skeletal complications in these patients. |
CE Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
Webcast from Live ASHP 2004 Meeting
Trends in Bone Metastases Therapy: Evolving Role of Health-System Pharmacies, we will not only give you an overview of bone metastases and available bisphosphonates, we will also look at economic implications of these therapies and the effects of their use on existing health systems. |
CME Webcasts |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to See Webcast Information!
View Activity Online
Join us online for this informative symposium on
managed care implications of emerging therapies in metastatic colorectal cancer (MCRC) |
Slide Set |
This activity has reached its termination date and no longer offers continuing education credit.
Download Slides from this Activity
This activity is designed for healthcare providers interested in the latest research on proteomic techniques developed for cancer diagnosis and therapeutics. The goal of this activity is to consider current research in the detection of early stage ovarian cancer and the clinical impact these new diagnostics may have on ovarian cancer patients |
CME Newsletter Series |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to View & Listen On-line/Order Newsletters
Each issue in this 5-part series consists of a Tx Reporter newsletter, an audio CD featuring an interview of the expert faculty on related issues, and a recent reprint with information that has largely determined the current standard of care. These issues focus on the next generation of bisphosphonate therapy. However, fair balance is critical to this discussion, and the faculty and I also present data on other bisphosphonates.
  |
CME Newsletter Series |
This activity has reached its termination date and no longer offers continuing education credit.
Click here to Download/Order Newsletters
Welcome to this 12-part case-based series. Case Studies in Recurrent Gynecologic and Lung Cancer: Chemotherapeutic Innovation addresses various dilemmas and options in treating non–small-cell lung cancer and ovarian cancer.
Learn about the most recent clinical trial results, innovative sequencing strategies, and the latest thinking on unique combination therapies. |
Slide Kit |
This activity has reached its termination date and no longer offers continuing education credit.
Download PowerPoint Slide Kit
This slide kit is designed as a teaching material for your use in any CME lectures or presentations you may give, or for other professional activities for which it may be useful. Its purpose is to help you educate clinicians about key clinical issues in the diagnosis and management of Superficial Bladder Cancer, including new treatment approaches. |
 CME Newsletter |
This activity has reached its termination date and no longer offers continuing education credit.
View/Download Newsletter
A challenging issue in the management of prostate cancer is the optimal time to begin chemotherapy. Whereas some clinicians advocate for a “watchful waiting” approach, others opt for initiating chemotherapy immediately after diagnosis. Another issue of debate is the appropriate time to refer a patient with prostate cancer for treatment. Two case studies are presented in this newsletter, which address the optimal time to initiate treatment and offer practical strategies for individualizing patient care. |
Monograph |
This activity has reached its termination date and no longer offers continuing education credit.
Download Monograph and accompanying slides
Hear from the experts in this engaging monograph on the most up-to-date findings on treatment for superficial bladder cancer. As a special feature, you can download 13 slides that will reinforce the experts' key points. |
 CME Newsletter Series |
This activity has reached its termination date and no longer offers continuing education credit.
| Download Newsletters I, II, III, IV |
| In this unique, new four-part Tx Reporter series, Dr. Michael A. O’Donnell answers FAQs on Intravesical Immunotherapy for superficial bladder cancer based on his many years of practice treating patients. |
|
CME Webcast |
This activity has reached its termination date and no longer offers continuing education credit.
| View Web Cast Replay |
| View a web cast replay of this live, satellite broadcast that puts the latest data into perspective and assess the benefits of aromatase inhibitors and other endocrine therapies for women with advanced breast cancer. Order newsletter online. Real Player G2 format. |
|
CME Newsletter Series |
This activity has reached its termination date and no longer offers continuing education credit.
| Download Newsletters: I, II, III, IV |
| These newsletters provide critical insight into the management of high-grade transitional cell carcinoma (TCC) to optimize treatment outcomes for patients with superficial bladder cancer. |
 Requires Acrobat Reader |
|
 CME Newsletters |
This activity has reached its termination date and no longer offers continuing education credit.
Order Newsletters: I, II, III
Recently, diagnosis and treatment of melanoma have undergone a series of important changes. These newsletters provide the latest findings from clinical trials in melanoma and update medical specialists on the implications of these trials for clinical practice. |
|
